Article info

Download PDFPDF

Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry

Authors

  1. a brendan.curti{at}providence.org
  2. b gdaniels{at}ucsd.edu
  3. c dmcdermo{at}bidmc.harvard.edu
  4. d JCLARK{at}lumc.edu
  5. e hk553{at}cinj.rutgers.edu
  6. f tlogan{at}iu.edu
  7. g jindis{at}axiommetrics.com
  8. h meenak{at}axiommetrics.com
  9. i tluna{at}prometheuslabs.com
  10. j nancy.gregory{at}prometheuslabs.com
  11. k michael.morse{at}duke.edu
  12. l michaelkwongmd{at}gmail.com
  13. m jpd4401{at}aol.com
View Full Text

Citation

Curti B, Daniels GA, McDermott DF, et al
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry

Publication history

  • Received September 8, 2017
  • Accepted November 30, 2017
  • First published December 19, 2017.
Online issue publication 
December 19, 2017

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.